News
IMUX
1.389
+0.67%
0.009
Weekly Report: what happened at IMUX last week (0708-0712)?
Weekly Report · 11h ago
Immunic appoints Jason Tardio as COO and President
Immunic appoints Jason Tardio as COO and President, effective July 12, 2024. The company also promotes Werner Gladdines to Chief Development Officer. Tardios most recently served as CEO of Ovid Therapeutics since June 2021. Immunic, Inc.
Seeking Alpha · 6d ago
Immunic Says Jason Tardio Will Be Joining Company As COO And President, Effective July 12, 2024
Benzinga · 6d ago
IMMUNIC- JASON TARDIO WILL BE JOINING CO AS CHIEF OPERATING OFFICER & PRESIDENT EFFECTIVE JULY 12 2024
Reuters · 6d ago
Press Release: Immunic Appoints Jason Tardio as -2-
Dow Jones · 6d ago
*Immunic Appoints Jason Tardio As Chief Operating Officer And President >IMUX
Dow Jones · 6d ago
Press Release: Immunic Appoints Jason Tardio as Chief Operating Officer and President
Dow Jones · 6d ago
Immunic Stock (IMUX): Understanding the Current Status and Future Path for IMU-838
TipRanks · 07/08 10:41
Weekly Report: what happened at IMUX last week (0701-0705)?
Weekly Report · 07/08 09:18
Weekly Report: what happened at IMUX last week (0624-0628)?
Weekly Report · 07/01 09:18
Immunic Stock (IMUX): Deep Dive into Lead Candidate, Vidofludimus Calcium
TipRanks · 06/24 09:39
Weekly Report: what happened at IMUX last week (0617-0621)?
Weekly Report · 06/24 09:19
Immunic, Inc.'s (NASDAQ:IMUX) latest 15% decline adds to one-year losses, hedge funds investors may consider drastic measures
Hedge funds own 39% of Immunic, Inc. (NASDAQ:IMUX) The top 7 shareholders own 51% of the company. The company has a market cap of US$103m. Hedge funds investors were most impacted by the recent drop in Immunic's share price. High institutional ownership implies the company's stock price is sensitive to their trading actions. Immunic is owned by a group of hedge funds with a 39% stake in the firm. It's worth looking at the diversity of its shareholders to see how the company operates.
Simply Wall St · 06/19 10:08
Weekly Report: what happened at IMUX last week (0610-0614)?
Weekly Report · 06/17 09:17
IMMUNIC-FILES PROSPECTUS SUPPLEMENT FOR SALE $80.0 MLN OF SHARES OF COMMON STOCK, MAY OFFER & SELL FROM TIME TO TIME THROUGH LEERINK PARTNERS
Reuters · 06/10 20:15
IMMUNIC INC -HAD PREVIOUSLY ENTERED INTO SALES AGREEMENT WITH LEERINK PARTNERS DATED MAY 2, 2022 RELATING TO SHARES OF COMMON STOCK
Reuters · 06/10 20:15
Weekly Report: what happened at IMUX last week (0603-0607)?
Weekly Report · 06/10 09:18
Immunic Stock (IMUX): Striving to Develop Innovative Therapies
TipRanks · 06/10 07:33
Weekly Report: what happened at IMUX last week (0527-0531)?
Weekly Report · 06/03 09:19
Weekly Report: what happened at IMUX last week (0520-0524)?
Weekly Report · 05/27 09:19
More
Webull provides a variety of real-time IMUX stock news. You can receive the latest news about Immunic Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMUX
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.